Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017 - Research and Markets

Research and Markets
Posted on: 18 Dec 17

The "Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 17, 13, 1, 63 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Idiopathic Pulmonary Fibrosis - Overview
  3. Idiopathic Pulmonary Fibrosis - Therapeutics Development
  4. Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
  5. Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
  6. Idiopathic Pulmonary Fibrosis - Drug Profiles
  7. Idiopathic Pulmonary Fibrosis - Dormant Projects
  8. Idiopathic Pulmonary Fibrosis - Discontinued Products
  9. Idiopathic Pulmonary Fibrosis - Product Development Milestones
  10. Appendix
  • Abeome Corp
  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • Nuevolution AB
  • Nuformix Ltd
  • Pharmaxis Ltd
  • Promedior Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Samumed LLC
  • Sanofi
  • Vicore Pharma AB
  • Yuhan Corp
  • Zai Lab Ltd

For more information about this report visit

View source version on

Business Wire

Last updated on: 18/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.